- Conditions
- Intracranial Atherosclerotic Disease, Stroke, Angioplasty, Balloon, Hemodynamics, Device Safety
- Interventions
- Submaximal balloon angioplasty
- Device
- Lead sponsor
- Case Western Reserve University
- Other
- Eligibility
- 30 Years to 90 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 961–984
of 33,591
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Blinatumomab, Low-intensity chemotherapy regimen, SOC chemotherapy regimen
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 40 Years to 100 Years
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 7
- States / cities
- Duarte, California • Orange, California • San Francisco, California + 4 more
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- filgrastim, therapeutic autologous lymphocytes, cyclophosphamide, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Melanoma
- Interventions
- injection of mouse TYRP2 DNA
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Painful Bladder Syndrome, Interstitial Cystitis, Bladder Pain Syndrome
- Interventions
- URG101, Placebo
- Drug
- Lead sponsor
- Urigen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 6
- States / cities
- Glendora, California • San Diego, California • Cartersville, Georgia + 1 more
- Conditions
- Plaque Psoriasis
- Interventions
- JNJ-77242113, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Sacramento, California • Ocala, Florida + 18 more
- Conditions
- COVID-19
- Interventions
- Placebo for SLV213, SLV213
- Other · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Hand-Foot Skin Reaction (HFSR)
- Interventions
- OQL011, Vehicle Ointment
- Drug
- Lead sponsor
- OnQuality Pharmaceuticals (USA) LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 15
- States / cities
- Goodyear, Arizona • Whittier, California • Aurora, Colorado + 12 more
- Conditions
- Lymphoma, Follicular
- Interventions
- Ofatumumab, Bendamustine infusion, Ofatumumab and Bendamustine infusions (Arm A), Bendamustine infusion (Arm B)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • Beverly Hills, California • Palm Springs, California + 15 more
- Conditions
- Acute Bacterial Skin and Skin Structure Infection
- Interventions
- Oritavancin, Warfarin
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Somers Point, New Jersey
- Conditions
- Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative
- Interventions
- GW597599
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 624 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 17
- States / cities
- Little Rock, Arkansas • Glendale, California • Laguna Hills, California + 13 more
- Conditions
- Primary Mitochondrial Disease
- Interventions
- Elamipretide, Placebo
- Drug
- Lead sponsor
- Stealth BioTherapeutics Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 4
- States / cities
- San Diego, California • Boston, Massachusetts • Akron, Ohio + 1 more
- Conditions
- Liver Transplant Recipient
- Interventions
- Tacrolimus (reduced tacrolimus), Everolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination), Everolimus (tacrolimus elimination), Tacrolimus (tacrolimus control), Corticosteroids
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 20 Years to 75 Years
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 15
- States / cities
- Washington D.C., District of Columbia • Tampa, Florida • Lexington, Kentucky + 10 more
- Conditions
- Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Genital Neoplasm, Female, Abdominal Neoplasm, Recurrence
- Interventions
- AB-1015
- Biological
- Lead sponsor
- Arsenal Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 8
- States / cities
- San Francisco, California • Aurora, Colorado • Iowa City, Iowa + 5 more
- Conditions
- Huntington's Disease
- Interventions
- Pridopidine
- Drug
- Lead sponsor
- Prilenia
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 8 more
- Conditions
- Healthy
- Interventions
- Selpercatinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Interventions
- IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin, Olaparib, Niraparib
- Drug
- Lead sponsor
- Imunon
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 11
- States / cities
- Orlando, Florida • New Orleans, Louisiana • Detroit, Michigan + 8 more
- Conditions
- Autism Spectrum Disorder
- Interventions
- Balovaptan, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 322 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 32
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Rogers, Arkansas + 27 more
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome, SARS-CoV-2, Hypoxemia
- Interventions
- Rejuveinix (RJX) Active Comparator, Placebo Comparator
- Drug
- Lead sponsor
- Reven Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Houston, Texas • New Braunfels, Texas
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Intervention C Daridorexant, Intervention C Placebo
- Drug
- Lead sponsor
- Global Coalition for Adaptive Research
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2029
- U.S. locations
- 9
- States / cities
- Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more
- Conditions
- Urinary Tract Infections
- Interventions
- LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose, LBP-EC01 IV Infusion Dose, Placebo, LBP-EC01, TMP/SMX
- Drug
- Lead sponsor
- Locus Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 17
- States / cities
- Fresno, California • Lancaster, California • Los Angeles, California + 13 more
- Conditions
- Traumatic Brain Injury
- Interventions
- Armodafinil, Placebo
- Drug · Other
- Lead sponsor
- Cephalon, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 53 more
- Conditions
- Alzheimers Disease
- Interventions
- RO7126209, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 15
- States / cities
- Atlantis, Florida • Clermont, Florida • Lady Lake, Florida + 12 more
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- sparsentan, irbesartan, Dapagliflozin
- Drug
- Lead sponsor
- Travere Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Glendale, California + 34 more